head JofIMAB
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski Publishing
ISSN: 1312-773X (Online)
Issue: 2017, vol. 23, issue 2
Subject Area: Dental Medicine - Oral Surgery
DOI: 10.5272/jimab.2017232.1536
Published online: 05 May 2017

Case Report

J of IMAB 2017 Apr-Jun;23(2):1536-1540
Atanaska S. Dinkova1ORCID logoCorresponding Autoremail, Dimitar T. Atanasov1ORCID logo, Ludmila G. Vladimirova-Kitova2ORCID logo,
1) Department of Oral Surgery, Faculty of Dental Medicine, Medical University - Plovdiv, Bulgaria,
2) Clinic of Cardiology, Faculty of Medicine, Medical University - Plovdiv, Bulgaria.

For more than 50 years, vitamin K antagonists have been the gold standard in the treatment of cardiovascular and cerebrovascular diseases and in the prevention of their complications. In the last 5 years new anticoagulants dabigatran, rivaroxaban and apixaban are rapidly implemented in the clinical practice, displacing Vit. K antagonists, due to numerous of advantages they have. Dabigatran is the first and most widely used new oral anticoagulant, so it is important for the dentists to be aware of this drug.
The purpose of this article is to review NOA dabigatran, its monitoring and reversal, and provides clinical advice on the management of patients who receives dabigatran and requires dental extractions.
Material and methods: The course of five patients on dabigatran who underwent teeth extraction was assessed. The medical charts of these patients were investigated. Morning dose of dabigatran (Pradaxa) was omitted and teeth extraction was performed ≥12 hours after the last intake of the drug.
Results: Fourteen teeth were extracted in five patients receiving Dabigatran with normal creatinine clearance. Extractions were performed ≥12 hours after the last administration of dabigatran. Only one patient has slightly prolonged bleeding, successfully controlled with local hemostatic measures.
Conclusions: Simple teeth extractions can be safely performed ≥12 hours after the last administration of the medication in patients with normal creatinine clearance without significantly greater bleeding risk than conventional oral anticoagulants. However, currently no established evidence-based guidelines for dental management of these patients are available and further clinical studies are needed.

Keywords: anticoagulants, dabigatran, dental extraction, hemostasis,

pdf - Download FULL TEXT /PDF 490 KB/
Please cite this article in PubMed Style or AMA (American Medical Association) Style:
Dinkova AS, Atanasov DT, Vladimirova-Kitova LG. Dabigatran and dental extraction - Case report. J of IMAB. 2017 Jan-Mar;23(2):1536-1540. DOI: 10.5272/jimab.2017232.1536

Corresponding AutorCorrespondence to: Atanaska Spasova Dinkova, DMD, DDS; Department Oral surgery, Faculty of dental medicine, Medical University – Plovdiv; 3, Hristo Botev blvd., 4000 Plovdiv, Bulgaria; E-mail: dinkova_asia@yahoo.com

1. Firriolo FJ, Hupp WS. Beyond warfarin: the new generation of oral anticoagulants and their implications for the management of dental patients. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Apr;113(4):431-41. [PubMed] [CrossRef]
2. Costantinides F, Rizzo R, Pascazio L, Maglione M. Managing patients taking novel oral anticoagulants (NOAs) in dentistry: a discussion paper on clinical implications. BMC Oral Health. 2016 Jan 28;16:5. [PubMed] [CrossRef]
3. Lixiana (edoxaban). European Medicines Agency. 3 July 2015. [Internet]
4. Mekaj YH, Mekaj AY, Duci SB, Miftari EI. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. TherClin Risk Manag. 2015 Jun;11:967-77. [PubMed] [CrossRef]
5. O’Connell JE, Stassen LFA. New oral anticoagulants and their implications for dental patients. J Irish Dental Assoc. 2014 Jun-Jul;60(3):137-143.
6. Walden B, Moll S. Interruption of dabigatran therapy at times of surgery, colonoscopy and other procedures. HemOnc Today, November 25, 2011.
7. Van Ryn J, Stangier, J, Haertter S, Liesenfeld KH, Wienen W, Feuring M et al. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2011 Jun;103(6):1116-27. [PubMed] [CrossRef]
8. Little JW. New oral anticoagulants: will they replace warfarin? Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 May;113(5):575-80. [PubMed] [CrossRef]
9. Srihirun S, Sibmooh N. Dabigatran: A new oral anticoagulant. M Dent J. 2015 Jan-Apr;35(1):79-89.
10. Mingarro-de-León A, Chaveli-López B. Alternative to oral dicoumarin anticoagulants: Considerations in dental care. J ClinExp Dent. 2013 Dec;5(5):e273-8. [PubMed] [CrossRef]
11. Muñoz-Corcuera M, Ramírez-Martínez-Acitores L, López-Pintor RM, Casañas-Gil E,  Hernández-Vallejo G. Dabigatran: A new oral anticoagulant. Guidelines to follow in oral surgery procedures. A systematic review of the literature. Med Oral Patol Oral Cir Bucal. 2016 Nov 1;21(6):e679-e688. [PubMed] [CrossRef]
12. Morimoto Y, Yokoe C, Imai Y,Sugihara M, Futatsuki T. Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants. Journal of Dental Sciences. 2016 Mar;11(1):59-64 [CrossRef]
13. Romond KK, Miller CS, Henry RG. Dental management considerations for a patient taking dabigatran etexilate: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Sep;116(3):e191-195. [PubMed] [CrossRef]
14. Tsolka P. Dental Procedures in Patients with Atrial Fibrillation and New Oral Anticoagulants. Arrhythm Electrophysiol Rev. 2014 Aug;3(2):85-9. [PubMed] [CrossRef]
15.  Drugs@FDA: FDA Approved Drug Products. FDA. [Internet]
16. Pollack CV, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015 Aug 6;373(6):511-20. [PubMed]
17. Davis C, Robertson C, Shivakumar S, Lee M. Implications of Dabigatran, a Direct Thrombin Inhibitor, for Oral Surgery Practice. J Can Dent Assoc. 2013; 79:d74. [PubMed]
18. Breik O, Cheng A, Sambrook PJ, Goss AN. Protocol in managing oral surgical patients taking dabigatran. Aust Dent J.  2014 Sep;59(3):296-301; quiz 401. [PubMed] [CrossRef]
19. Yoshikawa H, Yoshida M, Kimura S, Nagai K, Fukumoto S. [Clinical study of tooth extraction in patients receiving dabigatran.] [in Japanese] Jap J of Oral and Max Fax Surg. 2016; 62(6): 315-20. [CrossRef]
20. Weitz JI, Quinlan DJ, Eikelboom JW. Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation. 2012 Nov;126(20):2428-32. [PubMed] [CrossRef]
21. Gómez-Moreno G, Aguilar-Salvatierra A, Martín-Piedra MA, Guardia J, Calvo-Guirado JL, Cabrera M, et al. Dabigatran and rivaroxaban, new oral anticoagulants. new approaches in dentistry. J ClinExp Dent. 2010; 2(1):e1-5. [CrossRef]
22. Elad S, Marshall J, Meyerowitz C, Connolly G. Novel anticoagulants: general overview and practical considerations for dental practitioners. Oral Dis. 2016 Jan;22(1):23-32. [PubMed] [CrossRef]
23. Thean D, Alberghini M. Anticoagulant therapy and its impact on dental patients: a review. Aust Dent J. 2016 Jun;61(2):149-56. [PubMed] [CrossRef].

Received: 16 February 2017
Published online: 05 May 2017

back to Online Journal